Drug: MDMA-Assisted Therapy

What It Is

MDMA-assisted therapy is a supervised treatment studied for post-traumatic stress disorder, in which a screened patient takes MDMA a small number of times inside a course of psychotherapy. The drug is not taken alone or repeatedly. In the trials each person had preparatory sessions, three day-long sessions with MDMA and two trained therapists present, and integration sessions afterward to work through what came up. This page is the deep account of that research. The broader overview of psilocybin, ketamine, and the field as a whole sits on the psychedelics page.

MDMA (3,4-methylenedioxymethamphetamine) is the same compound sold illegally as ecstasy or molly. The studied treatment and recreational use share a molecule and almost nothing else: different doses, a screened patient, medical monitoring, and a structured course of therapy. This page carries no dosing and no sourcing.

What It Does

The evidence is graded claim by claim in the research section below. Two phase 3 trials are the core of it. In the first, MAPP1, ninety adults with severe PTSD were randomized to three MDMA sessions with therapy or to the same therapy with an inactive placebo. PTSD severity on the CAPS-5 scale, which runs from 0 to 80, fell by 24.4 points with MDMA against 13.9 points with placebo, a between-group effect size of d=0.91. The second trial, MAPP2, enrolled a more diverse group of 104 people with moderate-to-severe PTSD and found a smaller but still clear benefit, a CAPS-5 drop of 23.7 points against 14.8, d=0.7. Both trials also improved day-to-day functioning, and both were generally well tolerated over the study period.

That is a meaningful signal for a condition where current treatments help only some people. It sits against a limit that runs through the whole field. MDMA produces effects a person notices, so in a trial almost everyone can tell whether they received the drug or the placebo. A 2026 systematic review found that in inert-placebo MDMA trials more than 85 percent of participants correctly guessed their assignment, and across the wider set of psychedelic trials most did not even measure blinding. This is called functional unblinding, and when a person knows they received a treatment they hoped would work, expectation can lift their scores.

It does not mean the benefit is absent. It means the measured size of the effect is likely inflated, and the true effect is not yet established.

The clearest check on overstatement came from regulators. Despite the two positive trials, in 2024 the FDA declined to approve MDMA-assisted therapy for PTSD and asked for another phase 3 study, pointing to the weak blinding, the lack of an active comparator, limited data on how long the benefit lasts, and questions about how the trials were conducted. A positive trial and a convincing one are not always the same. The decision reads as a statement about the strength of the evidence, not a finding that the treatment does nothing.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Evidence And Methods

In MDMA trials most participants and raters correctly guess who received the drug, which inflates the measured benefitModerate · mixed

In plain terms

In MDMA trials almost everyone can tell whether they got the drug, which lets expectation inflate the measured benefit.

In detail

The PRISMA systematic review covered 112 randomized trials of psychedelics for psychiatric disorders (11 MDMA, plus psilocybin, LSD, ketamine, ayahuasca, DMT). Functional unblinding, defined as participants or raters correctly identifying treatment allocation from subjective effects, was pervasive; inert-placebo-controlled MDMA trials exceeded 85%. The review concluded that this pervasive unblinding raises concerns about the validity of efficacy findings.

The study · 1

Orsini et al., blinding integrity in psychedelic randomized clinical trials, a systematic review · JAMA Psychiatry 2026 (online)

In 2024 the FDA declined to approve MDMA-assisted therapy for PTSD and asked for another trialModerate · mixed

In plain terms

Regulators judged the two positive trials not yet convincing enough and asked for another one before any approval.

In detail

A 2026 commentary in the trauma-stress literature, responding to a State of the Science review of MDMA-assisted psychotherapy, argued that the evidence base remains constrained by difficulties in blinding, expectancy effects, the absence of robust active comparators, limited mechanistic clarity, and concerns about safety monitoring and generalizability, and that durability of gains rather than short-term symptom reduction should be the standard for adoption. These are the same dimensions the FDA cited in declining approval and requesting a further trial.

The study · 1

Suhardita et al., from therapeutic promise to evidentiary discipline, reassessing MDMA-assisted psychotherapy · J Trauma Stress 2026

How it works

MDMA releases serotonin along with dopamine and noradrenaline, lowering fear and raising trustModerate · mixed

In plain terms

MDMA floods the brain with serotonin, which lowers fear and raises trust, making painful memories easier to work through in therapy.

In detail

MDMA acts mainly by triggering release of serotonin through the serotonin transporter, along with dopamine and noradrenaline. The serotonin rise lowers the brain's fear response and raises feelings of trust and closeness, which is the basis for using it to help people stay with traumatic memories during therapy. The link from this pharmacology to durable symptom change is still being worked out, and the same monoamine release drives the acute cardiovascular and temperature effects.

The study · 1

Nichols, psychedelics, a comprehensive review · Pharmacol Rev 2016;68:264-355

Mood & stress

MDMA-assisted therapy lowered severe PTSD scores more than placebo with therapy in a phase 3 trialEmerging

In plain terms

In a phase 3 trial, adding MDMA to a course of therapy eased severe PTSD more than the same therapy with a placebo.

In detail

This randomized, double-blind, placebo-controlled multi-site phase 3 trial (NCT03537014) enrolled 90 adults with severe PTSD, including people with dissociation, depression, and substance-use histories. After medication washout, participants were randomized 1:1 to manualized therapy with MDMA or with placebo, each combined with three preparatory and nine integrative sessions. Mean CAPS-5 change in completers was -24.4 (SD 11.6) with MDMA and -13.9 (SD 11.5) with placebo. MDMA did not induce adverse events of abuse potential, suicidality, or QT prolongation over the study.

The study · 1

Mitchell et al., MDMA-assisted therapy for severe PTSD, a randomized double-blind placebo-controlled phase 3 study · Nat Med 2021;27:1025-1033

A confirmatory phase 3 trial again found MDMA-assisted therapy beat placebo with therapy for moderate-to-severe PTSDEmerging

In plain terms

A second phase 3 trial in a more diverse group again found MDMA plus therapy eased PTSD more than therapy with a placebo, by a somewhat smaller amount.

In detail

This randomized, placebo-controlled phase 3 trial (NCT04077437) enrolled 104 adults, of whom 26.9% had moderate and 73.1% had severe PTSD; 33.7% identified as other than White. Participants were randomized to MDMA-assisted therapy (n=53) or placebo with therapy (n=51), assessed by blinded independent raters. LS mean CAPS-5 change was -23.7 (95% CI -26.94 to -20.44) with MDMA versus -14.8 (95% CI -18.28 to -11.28) with placebo. Seven participants had a severe treatment-emergent adverse event (5 MDMA, 2 placebo); there were no deaths or serious adverse events.

The study · 1

Mitchell et al., MDMA-assisted therapy for moderate to severe PTSD, a randomized placebo-controlled phase 3 trial · Nat Med 2023;29:2473-2480

Cognition

Heavy recreational MDMA use may harm serotonin neurons, but human evidence is confounded by polydrug usePreliminary · risk

In plain terms

Heavy ecstasy use may harm serotonin-releasing neurons and memory, but the human evidence is tangled up with other drug use.

In detail

MDMA causes lasting reductions in serotonin markers in animals, including primates, and some studies link heavy recreational ecstasy use to cognitive and neuroimaging changes. In humans this is difficult to establish, because most heavy users also take other drugs and the research relies on self-reported past use. The neurotoxicity seen in animals used higher and more frequent doses than a supervised therapeutic session, and confounding by polydrug use and reliance on self-report weaken the human cognitive findings.

The study · 1

Montgomery et al., neurological and cognitive alterations induced by MDMA in humans · Exp Neurol 2022;347:113888

How It Works

MDMA acts mainly by causing the brain to release serotonin, along with dopamine and noradrenaline. The rise in serotonin lowers the fear response and raises feelings of trust and closeness. In therapy the aim is that a person can turn toward a traumatic memory, and stay with it long enough to process it, while the usual flood of fear is dampened and a trusted therapist is present. The idea is that the change outlasts the drug, learned during the session rather than produced by it.

What Happens Across a Course of Treatment

1The single session

MDMA reaches its peak effect over a few hours. Serotonin release lowers activity in the fear circuitry of the brain and raises a sense of safety and openness, which is what lets a person approach memories that are ordinarily too distressing to hold. The same release of noradrenaline raises heart rate, blood pressure, and body temperature, which is why medical monitoring is part of the studied setting.

2Between and after sessions

The trials used only three MDMA sessions, spaced weeks apart, each followed by integration therapy without the drug. The working idea is that the drug opens a window in which trauma can be reprocessed, and that the therapy, not the chemistry, is what carries the change forward. This is a different pattern from recreational use, where the same dose is taken often and without support.

3The unresolved part

How a few sessions produce lasting symptom change is still being worked out, and the durability of the benefit past the end of the trials is one of the open questions regulators raised. The pharmacology is well described; the link from a serotonin surge to a durable recovery is not yet settled.

The Legal Position

The law and the research are not in the same place. In the United States MDMA is Schedule I federally, the most restricted category, so outside an authorized research or approved-treatment setting its use is illegal. There is no state-regulated adult-use framework for MDMA of the kind Oregon and Colorado created for psilocybin. Because the FDA declined approval in 2024, MDMA-assisted therapy is not an available treatment; it is reachable only inside clinical trials and expanded-access programs. None of this page is a route to obtaining MDMA. It is a description of where the law and the science currently stand.

The Chinese Medicine View

Chinese medicine has a long-standing frame for altered states of mind, and it leans toward caution. The Heart is said to house the Shen, the spirit or consciousness, and clear thought, steady emotion, and restful sleep are read as signs of a settled Shen. A mind flooded, disoriented, or thrown into fear or agitation is described as a disturbance of the Shen, and the classical tradition treats such disturbance as something to calm and anchor. Trauma, in this language, reads as a lasting disturbance of the Shen and often of the Heart and Kidney, and the bias of the medicine is toward grounding: settling the Shen, harmonizing the Heart, and rooting a scattered mind back in the body through stillness, breath, and regular life.

Read through that lens, an intense, mind-altering session is not neutral. It could be seen as deliberately stirring the Shen in order to reach material that cannot otherwise be approached, which the tradition would treat with great care, especially in someone already depleted, agitated, or unsettled, and especially without skilled support and a calm setting. This is an interpretation, not a verdict, and not a claim that the tradition anticipated modern trials. It is offered because it lines up, in its own language, with what the clinical evidence keeps showing: that preparation, support, and a stable setting shape the outcome, and that a fragile person is the one most likely to be harmed. The wider preventive tradition of Yang Sheng, nourishing life, would place the emphasis on grounding practices first.

Cautions For This Practice

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

MDMA raises core body temperature and can cause dangerous hyperthermia at higher recreational doses

In controlled laboratory studies MDMA produced a dose-dependent rise in core body temperature of about 0.2 to 0.8 degrees C, and temperatures above 38 degrees C occurred often at higher doses even at rest and at room temperature. Severe hyperthermia is one of the recognized life-threatening complications of recreational MDMA use. The lab rises were modest and did not reach hyperpyrexia in a controlled setting; the severe cases come from higher uncontrolled doses, physical exertion, and hot environments.Liechti, effects of MDMA on body temperature in humans

Repeated full-dose MDMA is linked to heart-valve damage through the 5-HT2B receptor

MDMA is a partial agonist at the 5-HT2B serotonin receptor, the receptor tied to valvular heart disease from other drugs, and chronic ingestion of full doses of MDMA has been associated with valvular heart disease. The risk from single supervised therapeutic sessions has not been directly measured. No study designed to measure valve risk from therapeutic dosing exists, and the concern attaches to frequent or repeated use rather than the few sessions used in the trials.Tagen et al., the risk of chronic psychedelic and MDMA microdosing for valvular heart disease

This is not an available treatment, and this is not a guide to using MDMA

MDMA is Schedule I federally, MDMA-assisted therapy is not approved, and use outside a clinical trial is illegal in most places. This page carries no dosing, no sourcing, and no instructions. The trial results come from screened patients in prepared sessions with two trained therapists and medical monitoring, which is a very different situation from taking a substance alone or at a party.

Acute cardiovascular and temperature strain

MDMA raises heart rate, blood pressure, and core body temperature, and severe hyperthermia is one of its recognized life-threatening complications at higher uncontrolled doses, made worse by exertion and hot rooms. Drinking too much water to counter that heat has caused dangerous hyponatremia, a fall in blood sodium that can lead to seizures. Anyone with heart disease or a heat-sensitive condition is at higher risk.

Serotonin syndrome and drug interactions

Because MDMA releases serotonin, combining it with an MAOI antidepressant or other strongly serotonergic drugs can push serotonin to dangerous levels, a state called serotonin syndrome. SSRIs and SNRIs can also blunt the effect, which is why the trials washed medications out under supervision. Anyone on psychiatric medication is in interaction territory that a prescribing clinician should handle.

Who should not do this, and the neurotoxicity question

A personal or family history of bipolar disorder or of psychosis is the most important reason for caution, because these drugs can trigger mania or psychosis in vulnerable people. Separately, heavy repeated recreational use is linked to lasting reductions in serotonin markers in animals and to cognitive changes in some human studies, though the human evidence is confounded by polydrug use. That neurotoxicity concern attaches to frequent high-dose use, not to the few supervised sessions the trials used, and the two exposures should not be equated.

MDMA-assisted therapy is a promising area of trauma research and MDMA is a potent drug with real acute and, at heavy repeated exposure, longer-term risks. The stance here is to inform: read the evidence at its true strength, take the risks seriously, and, for anything touching your own care or medication, talk it through with a qualified clinician.

Common Questions

Does MDMA-assisted therapy work for PTSD?

Two phase 3 trials say it helps more than therapy with a placebo, with a moderate-to-large effect. In the first, PTSD severity on the CAPS-5 scale fell 24.4 points with MDMA against 13.9 with placebo; in the second, 23.7 against 14.8. The limit is that almost everyone could tell whether they got the drug, so expectation is mixed into the result and the true effect is probably smaller than those numbers. It is a meaningful signal held back by a blinding weakness in how the trials were run.

If the trials were positive, why did the FDA say no?

Because a positive trial and a convincing one are not the same thing. In 2024 the FDA declined to approve MDMA-assisted therapy for PTSD and asked for another trial. Regulators pointed to the functional unblinding, the absence of an active comparator, thin data on how long the benefit lasts, and questions about how the studies were run. It is a judgment about the strength of the evidence, not a claim that MDMA does nothing for trauma.

How is MDMA different from psilocybin or ketamine?

They are grouped together loosely but work differently. MDMA releases serotonin, lowering fear and raising trust, and is studied for PTSD. Psilocybin is a classic psychedelic that acts on the serotonin 5-HT2A receptor and is studied for depression and end-of-life distress. Ketamine and its approved relative esketamine act on the NMDA glutamate receptor and work quickly on mood. The psychedelics overview covers the others in full.

Is MDMA dangerous?

It carries real risks, which is why the trials screened people and monitored them. Acutely it raises heart rate, blood pressure, and body temperature, and severe overheating and hyponatremia are the dangers at higher uncontrolled doses. Combined with an MAOI or other serotonergic drug it can cause serotonin syndrome. A history of bipolar disorder or psychosis is a strong reason for caution. Heavy repeated recreational use is separately linked to possible harm to serotonin neurons. The supervised sessions in the trials are a different exposure from recreational use.

Go Deeper

• Psychedelics in mental health: the overview of the whole field, including psilocybin for depression, the approved relative esketamine, the blinding problem, and where the law stands.
• Anxiety: the condition that runs alongside much of this research, and the treatments with the strongest track record. PTSD is closely related, and the same grounding practices apply.